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Abstract  13 
Certain members of the microbiota genus Bifidobacterium, are known to positively influence host 14 
well-being. Importantly, reduced bifidobacterial levels are associated with Inflammatory Bowel 15 
Disease (IBD) patients, who also have impaired epithelial barrier function, including elevated rates of 16 
apoptotic extrusion of small intestinal epithelial cells from villi; a process, termed ‘cell shedding’. 17 
Using a mouse model of pathological cell shedding, we show that mice receiving B. breve UCC2003 18 
exhibit significantly reduced rates of small intestinal epithelial cell shedding. Bifidobacterial-induced 19 
protection appears to be mediated by a specific bifidobacterial surface exopolysaccharide and 20 
interactions with host MyD88 resulting in downregulation of intrinsic and extrinsic apoptotic 21 
responses to protect epithelial cells under highly apoptotic conditions. Our results reveal an 22 
important and previously undescribed role for B. breve, in positively modulating epithelial cell 23 
shedding outcomes via bacterial- and host-dependent factors, supporting the notion that 24 
manipulation of the microbiota affects intestinal disease outcomes. 25 
 26 
Key words 27 




Introduction  30 
Bifidobacteria represent one of the first colonisers of the infant gut and are prominent members of 31 
the adult gut microbiota [1, 2]. They have been linked to a number of health-promoting activities 32 
including the promotion of anti-tumour immunity [3], modulation of antimicrobial activities against 33 
pathogenic bacteria [4] and protection against relapse of Ulcerative Colitis [5, 6]. Despite these 34 
purported benefits, the molecular mechanisms underlying these protective effects by bifidobacteria 35 
remain largely unknown, although recently, components of their surface, including the 36 
exopolysaccharide (EPS) have been shown to play a significant role in modulating protective effects 37 
[7]. It is critical to obtain detailed insights into the mode of action by which microbiota members 38 
sustain and improve host health, as this will be central to future disease treatment/prevention 39 
strategies. 40 
There is a growing body of evidence suggesting that the microbiota influences intestinal epithelial 41 
cell (IEC) function, including gene expression, cell division and energy balance [8-11]. These 42 
symbiotic bacterial/host relationships have co-evolved to the extent that the microbiota is 43 
indispensable for the maintenance of gut homeostasis [12]. Importantly, microbial dysbiosis, as 44 
indicated by a reduction in overall diversity, including specific reductions in Bifidobacterium, has 45 
been linked to Inflammatory Bowel Disease (IBD) [13-15], underlining the critical importance of 46 
host/microbe interactions in maintaining a steady state within the intestine.  47 
The epithelium of the small intestine represents the first line of defence against entry of bacteria 48 
into host tissues. Cell division in the crypt, under physiological conditions, is counter-balanced by cell 49 
shedding from the villi to maintain homeostasis and integrity of the crypt/villus axis. When the 50 
epithelial cell is shed, a discontinuity in the villus epithelial monolayer is created, which potentially 51 
compromises the epithelial barrier. In health, epithelial barrier function is maintained [16], due to a 52 
dramatic redistribution of apical junction complex proteins including Zonula Occludin 1 (ZO-1), 53 
occludin 1 and E-cadherin, which form a funnel that surrounds the shedding cell and plugs the 54 
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resulting gap until the movement of neighbouring epithelial cells restores epithelial continuity [17-55 
19].  56 
TNF-α is a key cytokine in IBD. We and others, have shown that TNF-α induces apoptosis of villus tip 57 
epithelial cells causing excessive shedding, leading to breakdown of the epithelial barrier and micro-58 
ulceration [16, 20]. Delayed repair of epithelial defects caused by excessive cell shedding contributes 59 
to the development of macroscopic ulceration [21]. Our studies with confocal endomicroscopy of 60 
patients with IBD in clinical remission have demonstrated that those patients with high rates of cell 61 
shedding are more likely to relapse than those with low shedding rates, demonstrating a causative 62 
link between barrier function and the inflammatory response [21].  63 
Given reports of beneficial effects of certain members of the gut microbiota in IBD and potential 64 
roles of microbial dysbiosis in these diseases we hypothesized that certain health-promoting 65 
microbiota members, including Bifidobacterium, may play a role in protecting against the cell 66 
shedding response by modulating IEC function. To determine the contribution of bifidobacteria in 67 
cell shedding, we employed a well characterised in vivo mouse model in which pathological cell 68 
shedding is induced by intraperitoneal administration of Lipopolysaccharide (LPS), driving 69 
mononuclear cell expression of TNF-α and subsequent capase-3-positive shedding cells [22]. Our 70 
results suggest a particular bifidobacterial strain (i.e. human isolate B. breve UCC2003) positively 71 
modulates the small intestinal cell shedding response via host MyD88- and bacterial 72 
exopolysaccharide-dependent interactions which serve to significantly reduce apoptotic signalling in 73 
the epithelial compartment. This points at a previously unknown mechanism by which this 74 
Bifidobacterium microbiota member protects its host against pathological cell shedding. These 75 
findings may thus have important implications for the future design of therapeutic strategies in the 76 
context of intestinal diseases. 77 




C57 BL/6 Jax mice (6-10 weeks) were obtained from Charles River. Vil-cre Myd88 transgenic mice 80 
(i.e. Cre recombinase expression causes truncation and resulting non-function of the MYD88 protein 81 
in IECs) were obtained from the Wellcome Trust Sanger Centre (kind gift from S. Clare).  82 
Bacterial culture and inoculations 83 
Bifidobacterium breve strains UCC2003, UCC2003del and UCC2003inv were used for animal 84 
inoculations. These strains and corresponding culturing conditions have been previously described in 85 
detail [7]. In brief, colonies were established from frozen glycerol stocks onto reinforced clostridial 86 
agar (RCA) plates before being subcultured to reinforced clostridial medium (RCM) and subsequently 87 
Man Rogosa Sharpe (MRS) medium (Oxoid, Hampshire) under anaerobic conditions. Bacteria were 88 
then purified by centrifugation and washing in PBS containing L-cysteine before being reconstituted 89 
in sterile PBS at a final concentration of approximately 1 x 1010 bacteria mL-1. 0.1 mL of inoculum was 90 
then administered to mice by oral gavage in 3 x 24 h doses followed by plating of faecal pellets on 91 
RCA containing 50 mg L-1 mupirocin to confirm stable colonisation. Control mice received oral gavage 92 
of PBS only.  93 
LPS injections and tissue collections 94 
24 hours after the last doses of B. breve or PBS control, mice received an IP injection of 1.25 mg kg-1  95 
LPS from Escherichia coli 0111:B4 (Sigma) or sterile saline (control) and mice were sacrificed 90 96 
minutes post-challenge with LPS. Proximal small intestine was collected in 10% neutral buffered 97 
formalin saline (Sigma) and fixed for 24 h followed by paraffin embedding. Samples of proximal small 98 
intestine were also collected into RNA later (Manchester) for transcriptome analysis or frozen on dry 99 
ice for subsequent ELISA analysis. In some cases, proximal small intestine was also collected into 100 




5 μm sections of paraffin embedded small intestinal tissue were sectioned and used for 103 
immunohistochemistry. Following de-parafinisation and rehydration, tissue sections were treated 104 
with 1% hydrogen-peroxide in methanol to block endogenous peroxidases. Subsequently, slides 105 
were treated using heat-induced antigen retrieval in 0.01 M citrate acid buffer (pH 6) followed by 106 
incubation with a rabbit polyclonal anti-active Caspase-3 antibody (AF835:R&D systems). 107 
Visualisation of caspase-3 positivity was via a peroxidase-labelled anti-rabbit EnVision™ secondary 108 
antibody (Dako) and 3,3'-diaminobenzidine followed by counterstaining with haematoxylin. For 109 
macrophage staining, antibody against F4/80 antigen (ab6640:Abcam) was employed using 110 
biotinylated anti-rat (BA-9401) and Avidin-Biotin reagent (PK-6100) (Vector laboratories). 111 
Quantification of caspase-3 positivity 112 
IECs were counted on a cell positional basis from villus tip (Cell position (CP) 1) down towards the 113 
crypts under 400x magnification. 20 well orientated hemi-villi were counted per mouse and analysed 114 
using the Score, WinCrypts [23] and PRISM analysis software. IECs were defined as “normal” in cases 115 
where staining for active Caspase-3 was absent. Immuno-labelled cells with either unaltered or 116 
shedding morphology were treated as caspase-3 positive. Imaging was performed with an Olympus 117 
BX60 microscope and C10plus digital camera. 118 
RNA isolation and real-time PCR 119 
Samples fixed in RNAlater solution were processed through RNeasy plus mini spin columns to isolate 120 
total RNA (Qiagen). In brief, samples were homogenised using a rotor stator hand held homogeniser 121 
in buffer RLT before processing through a QIAshredder column and subsequently RNeasy mini-spin 122 
columns. Purified RNA was eluted into RNAase free water. Reverse transcription was performed 123 
using the Quantitect reverse transcription kit (Qiagen) and cDNA used for real-time PCR analysis. For 124 
real-time PCR, transcripts were amplified using Quantifast SYBR green mastermix (Qiagen) and 125 
Quantitect primer assays for TNF-α, TNF-R1, and F4/80 (EMR1). Expression of the housekeeping 126 
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gene Hypoxanthine-guanine phosphoribosyltransferase (HPRT; 5’-GACCAGTCAACAGGGGACAT-3’ 127 
(sense) and 5’-AGGTTTCTACCAGTTCCAGC-3’ (antisense) [24] was also determined. Cycling was 128 
performed on a Roche LightCycler 480 using the following conditions: 95oC, 5 min then 40 cycles of 129 
95oC, 10 s; 60oC, 35 s. Relative quantification of levels of transcript expression was calculated using 130 
the Pfaffl method [25] by comparing cycle threshold (Ct) value of each target gene to the CTvalue of 131 
housekeeper. Data are presented as a ‘‘fold change’’ in expression (normalized against control 132 
untreated mice/cells). 133 
Isolation of IECs and FACS analysis 134 
IECs were isolated using a modification of the Weiser methodology [26]. In brief, whole small 135 
intestine was collected in ice cold HBSS before being chopped into 0.5 cm2 pieces and washed in a 136 
solution containing 0.154 M NaCl and 1 mM DTT and subsequently a solution containing 1.5 mM KCl, 137 
96 mM NaCl, 27 mM Tri-sodium citrate, 8 mM NaH2PO4 and 5.6 mM Na2HPO4, pH 7.3. IECs were 138 
then isolated by incubation in PBS containing 1.5 mM EDTA and 0.5 mM DTT, shaking at 200 rpm and 139 
at 37oC. Purity of epithelial preparations was confirmed by histological analysis of stripped intestinal 140 
mucosa and by FACS analysis of isolated cells. For FACS analysis 5x106 cells were stained with anti-141 
mouse CD45-A700 (Biolegend) on ice for 30 min. After two washes in HBSS containing 0.01 BSA, 2 142 
mM EDTA, 20 mM HEPES, 0.01% NaN3, propidium iodide was added (Biolegend) and samples 143 
analysed on a Sony FCS SH-800 flow cytometer. Data were analysed using FlowJo (TreeStar). 144 
ELISA 145 
Frozen proximal small intestinal samples were homogenised in extraction buffer containing protease 146 
inhibitors (Roche), cleared by centrifugation and analysed using a commercial ELISA kit TNF-α 147 
(eBioscience) as per manufacturer’s protocol. Measurement of TNF-α immunoreactivity was at 450 148 
nm using a Fluostar Optima plate reader (BMG Labtech). 149 
Native PAGE, SDS-PAGE and Western blotting 150 
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Isolated intestinal epithelial cells were lysed in CelLytic MT reagent (Sigma) before centrifugation at 151 
10,000 rpm for 10 minutes to pellet cellular debris. Supernatants were mixed with 2 x Laemmli 152 
sample buffer before being separated by sodium dodecyl sulfate (SDS)-PAGE with 3-14% acrylamide 153 
gel and transferred to Hybond-P PVDF membrane (GE Healthcare, Buckinghamshire, UK) and 154 
blocking with 5% marvel in with tris(hydroxymethyl)aminomethane. (Tris)-buffered saline containing 155 
Tween 20 (TTBS), immuno-staining was performed with 1/1000  156 
anti-TNF-R1 antibody (Abcam) and 1/5000 Goat anti-Rabbit IgG HRP conjugate (Millipore) on 157 
reduced gel. Macrophage expression was analysed similarly using antibody against F4/80 antigen 158 
(Abcam) at 1:1000 and goat anti-rat IgG-HRP (SantaCruz, at 1:3000), on a non-reduced gel. Washes 159 
were in TTBS. For detection, ImmobilonTM Western chemiluminescent HRP substrate (Millipore) was 160 
applied to the membrane as recommended by the manufacturer and signal was detected using a 161 
FluorChem E imaging system (Protein Simple). Band densities were quantified using Fiji [27].  162 
PCR array analysis 163 
Real Time ready Custom Panel 480 – 96+ PCR arrays were obtained (Roche) and quantitative PCR 164 
analysis performed. RNA was extracted from whole small intestinal tissue preserved in RNAlater 165 
reagent (Sigma) using RNeasy plus mini kits (Qiagen). Reverse transcription was performed using 166 
Transcriptor First Strand cDNA Synthesis Kit followed by analysis of targets using LightCycler 480 167 
Probes Master on a LightCycler 480 platform (all Roche). Standard protocols as per manufacturer 168 
recommendations were followed. CT values of target genes were normalised to expression of the 169 
housekeeping gene HPRT and fold change versus control samples calculated using the delta/delta CT 170 
method [25].  171 
Statistical analysis  172 
Experimental results were plotted and analysed for statistical significance with Prism5 software 173 




Lipopolysaccharide induces cell shedding from small intestinal villi in a dose dependent manner 176 
Caspase-3 is activated in intestinal epithelial cells during their extrusion from the tips of small 177 
intestinal villi [18, 28]. Similar to previous reports, we found that control C57BL/6 mice receiving 178 
intra-peritoneal (IP) PBS injection showed low levels of cell shedding as evidenced by low level 179 
expression of cleaved caspase-3 (CC3) in the epithelial cell layer (Fig. 1A). Recent studies have 180 
demonstrated that following IP injection of mice with Lipopolysaccharide (LPS) isolated from 181 
Escherichia coli 0111:B4, a potent cell shedding response is induced, similar to that observed in 182 
relapsing IBD patients [22]. In agreement with these studies, we found a significant increase in CC3-183 
mediated cell shedding at 90 minutes post-injection of 1.25 mg kg-1 LPS, not only at the villus tip, but 184 
also along the shoulders and sides of the villus (Fig. 1B). Effects of LPS on the cell shedding response 185 
were found to be dose dependent, in agreement with previous observations [22] (data not shown). 186 
B. breve modulates LPS-induced cell shedding 187 
Various members of the microbiota are known to promote a healthy gut [29], although the precise 188 
mechanisms behind this remain incompletely understood. We reasoned that because the integrity of 189 
the intestinal epithelium is intrinsically linked to the well-being of the host and because the 190 
microbiota is expected to impact on epithelial crosstalk, such health-promoting species might play a 191 
role in regulating cell shedding. To test this, groups of C57 BL/6 mice were initially dosed with 192 
vehicle control (PBS) or with 1 x 109 B. breve UCC2003 (isolated from a healthy infant) in 3 x 24 h 193 
doses orally to establish stable colonisation [7]. Colonisation was confirmed by faecal CFU counts on 194 
day 4 (Fig. S1). Mice were then administered LPS to induce pathologic cell shedding, followed by 195 
sacrifice at 1.5 h. Following dosing with B. breve UCC2003 and induction of cell shedding with LPS, 196 
mice showed a marked reduction in the levels of CC3-positive shedding cells compared to LPS 197 
treated control mice receiving PBS gavage (Fig. 2A-B). Cell count analysis confirmed significant 198 
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reduction in cell shedding at the majority of positions along the length of the villus in B. breve 199 
UCC2003 treated mice (Fig. 2C; p< 0.001, ANOVA). Thus, B. breve appears to modulate epithelial 200 
integrity/survival during periods of inflammatory insult. 201 
Previous studies have indicated that bifidobacteria may modulate the composition of other 202 
microbiota members, and within the context of IBD, studies have linked microbiota disturbances 203 
with active disease. Thus, to determine if bifidobacterial colonisation impacts the gut microbiota, we 204 
analysed the community composition using a 16S rRNA-based sequencing approach. We found 205 
minor changes to the community structure in B. breve UCC2003 versus control treated mice 206 
(C57BL/6), but overall, no notable differences (but expected increase in Actinobacteria in the B. 207 
breve UCC2003 group) in microbiota class abundance between the treatment groups (Fig. S2). 208 
Bifidobacterial colonisation takes place along the gastrointestinal tract including the small/large 209 
intestine and caecum. RNAscope analysis showed that B. breve UCC2003 was found in intimate 210 
contact with the IECs of the small intestine in colonised C57BL/6 mice (Fig. S3). Together, these data 211 
suggest that colonisation with B. breve does not produce significant shifts in the overall gut 212 
microbiota community structure and that the observed protective effects after colonisation are 213 
more likely related to direct effects of B. breve , possibly through interactions with the intestinal 214 
epithelial cells. 215 
The mechanism of protection against LPS-induced cell shedding is TNF-α independent 216 
LPS-induced cell shedding is caused by the release of TNF-α from lamina propria tissue-resident 217 
macrophages, which binds to TNF-receptor 1 (TNF-R1), on intestinal epithelial cells [22], thereby 218 
driving the apoptotic response. Conditioning of macrophage responses by the microbiota has been 219 
reported previously [30] and, consistent with this data, bacteria such as B. breve have been 220 
described to possess immune-modulatory properties [31]. Thus, to determine whether the cell 221 
shedding outcome, as modulated by B. breve, was caused by reduced expression of TNF-α from 222 
macrophages, we isolated RNA and protein from whole small intestine of control and B. breve 223 
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UCC2003-treated C57BL/6 mice following LPS-mediated induction of cell shedding. As shown in Fig. 224 
3A no significant difference in levels of TNF-α protein was observed between groups and this was 225 
confirmed at the transcriptional level (data not shown). We also found no changes in expression of 226 
TNF-α in the plasma of B. breve UCC2003 -treated versus control mice following LPS-induced cell 227 
shedding (Fig. 3B) or any significant difference in the numbers/levels of F4/80+ macrophages 228 
infiltrating the small intestine (Fig. 3C-F). Together, these data suggest that modulation of the 229 
reduced cell shedding response is independent of TNF-α induction. Since the microbiota may be able 230 
to interact directly with IECs we postulated that B. breve modulates a signalling pathway 231 
downstream of the TNF-α ligand. To test whether expression of TNF-R1 was altered in the 232 
epithelium following dosing with B. breve UCC2003, IECs were isolated from whole small intestinal 233 
tissue using a modified Weiser methodology [32], after which purity of the IEC population was 234 
confirmed by histological analysis of stripped intestinal tissue and FACS analysis (Fig. 3G&H). 235 
Subsequent quantitative RT-PCR and Western blot analysis of isolated IEC populations showed no 236 
changes to expression of the TNF-R1 transcript or protein following exposure to B. breve UCC2003 237 
(Fig. 3I-K), suggesting that there is no impairment of signalling at the level of the receptor.  238 
Functional epithelial MyD88 signalling is required for B. breve-mediated protection against cell 239 
shedding  240 
Intestinal epithelial cells sample microbe-associated molecular patterns (MAMPS) of the intestinal 241 
luminal contents using a variety of receptors including members of Nucleotide-binding 242 
Oligomerization Domain (NOD) family, C-type lectin receptors (CLR) family and the Toll-like receptor 243 
(TLR) superfamily. MyD88 is a critical adaptor protein in signalling downstream of the majority of the 244 
TLR family members [33]. We thus used epithelial-specific (Vil-Cre) MyD88 knockout mice to 245 
determine whether B. breve elicits its protective effects via epithelial TLR signalling pathways. 246 
C57BL/6 MyD88-/- villin-cre mice (i.e. IEC MyD88 KO mice) colonised with B. breve UCC2003, showed 247 
similar rates of LPS-induced cell shedding to PBS gavaged IEC MyD88-/- mice. In comparison, control 248 
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mice (i.e. C57BL/6 MyD88+/+ villin-cre), showed the expected protection against cell shedding in the 249 
presence of B. breve  UCC2003 (Fig. 4A-D). Furthermore RT-PCR analysis of IEC homogenates showed 250 
increased expression of TLR2 in B. breve UCC2003 colonised mice when compared to control mice 251 
(i.e. PBS, Fig. 4E). Taken together, these data indicate that functional MyD88 signalling, potentially 252 
via TLR2is required for modulating the protective effect of B. breve against cell shedding outcomes.  253 
B. breve EPS plays a role in modulating protection against LPS-induced cell shedding  254 
Recently, a number of functions modulated by bifidobacteria have been shown to be mediated 255 
through surface-associated EPS including resistance to gut infection [7]. Interestingly, the eps gene 256 
clusters represent a relatively conserved feature of bifidobacterial genomes, including those of the 257 
species B. breve [34]. In order to investigate the role of EPS in modulating the response against cell 258 
shedding, we used a deletion mutant (B. breve UCC2003-EPSdel) that expresses neither EPS1 nor 259 
EPS2 [7]. Mice were stably colonised by dosing with B. breve EPS-positive or EPS-negative strains 260 
followed by challenge with LPS (Fig.S1). Strikingly, when colonised with the B. breve UCC2003-261 
EPSdel, no protection against cell shedding was observed in control (i.e. PBS) versus colonised mice 262 
(Fig. 5A&B).  263 
B. breve UCC2003 controls EPS biosynthesis via a bidirectional gene cluster which results in 264 
expression of either EPS1 (B. breve UCC2003) or EPS2 (B. breve UCC2003-EPSInv) [7]. Thus, to gain 265 
further insights into the role of a different EPS in the protective cell shedding response, we 266 
undertook studies using B. breve UCC2003-EPSInv. Colonisation with EPS2 expressing B. breve  (i.e. 267 
B. breve UCC2003-EPSInv) also failed to show any protection against LPS-induced cell shedding, 268 
suggesting considerable variation in the protective response dependent upon EPS genetic and 269 
chemical structure and organisation (Fig. 5C&D). All strains are directly compared in Fig.S4.  270 
Together, these studies emphasize the striking strain variant specificity that is observed with regard 271 
to the individual protective effects of these bacteria following LPS-induced cell shedding. This is 272 
13 
 
likely regulated by the specific molecules produced by each strain, including the EPS. This highlights 273 
the critical need to fully genetically characterise ‘probiotic’ strains of bacteria to enable a detailed 274 
dissection of their functional effects in vivo for optimal translation to human patients.  275 
 276 
B. breve EPS attenuates inflammatory and apoptosis signalling  277 
In order to gain further insight into the changes taking place in the small intestine following 278 
colonisation with B. breve UCC2003 and the influence of EPS, whole small intestinal samples from 279 
control (i.e. PBS) and colonised (EPS-positive, B. breve UCC2003 and EPS-negative, B. breve 280 
UCC2003-del) mice following challenge with LPS were analysed using a custom RT-PCR array (Fig. 6: 281 
49/84 targets are shown, full set of data is displayed in Fig. S5A&B) to look for transcriptional 282 
changes to key inflammatory transcripts and those involved in the apoptotic cascade. Interestingly, 283 
small intestinal samples from B. breve UCC2003-EPSdel colonised mice (Fig. 6A and Fig. S3A&B) 284 
showed significant increases (> 2-fold and p< 0.01) in IL-6 and Tnfrs15 when compared to control 285 
and LPS challenged mice. Moreover numerous other apoptotic and inflammatory genes were 286 
significantly upregulated (> 2-fold, p<0.01) including Bad, Cycs (Cytochrome C, Somatic), casp4, Fas, 287 
Traf5 and Tnfrs9. In contrast in EPS-positive colonised mice (i.e. B. breve UCC2003) our analysis 288 
showed only subtle changes to the expression of the majority of the targets, when compared to 289 
control LPS animals. In addition, whilst significant elevation (> 2-fold and p< 0.05) in IL-6 and Tnfrs15 290 
was observed following colonisation with B. breve UCC2003, Tnfrs15 expression was markedly 291 
decreased versus B. breve UCC2003-EPSdel colonised mice (3-fold vs 16-fold increase). These data 292 
suggest that signalling via EPS may downregulate inflammatory and apoptotic networks which would 293 




We report that colonisation of mice with B. breve significantly reduces pathological/apoptotic 296 
epithelial cell shedding, through a previously unknown mechanism involving bifidobacterial EPS-297 
MyD88 signalling. 298 
 299 
The gut microbiota appears central to maintaining epithelial barrier integrity and importantly 300 
disturbances in the microbiota appear pivotal in IBD pathogenesis. Indeed, IBD patients (paediatric 301 
and adult cohorts) have been shown to possess a reduced overall microbiota diversity and 302 
reductions in specific genera including Clostridium, Bacteroides, Faecalibacterium and, of particular 303 
interest here Bifidobacterium [6, 15, 35]. Previous clinical trials have shown that administration of 304 
bifidobacterial strains can reduce the incidence of relapse in patients suffering from IBD [36]. 305 
Following LPS-induced cell shedding, we observed that a priori administration of B. breve UCC2003 306 
(which is a human-isolated strain, thus more translationally relevant) conferred a significant level of 307 
protection which manifested as significantly reduced caspase-3 positivity within the villus epithelium 308 
(Fig. 2A-C). Previous studies have highlighted that bifidobacterial supplementation may also 309 
modulate the wider microbiota in mouse models [37]. However, our data indicates that whilst there 310 
are modest differences between PBS and B. breve colonised mice (as indicated by taxa abundance), 311 
there are no notable differences (with high variability between animals) suggesting limited effects on 312 
overall microbiota profiles (Fig. S1). These data therefore suggests a more direct link between 313 
bifidobacteria and maintenance of epithelial integrity in the prevention of intestinal inflammation.  314 
Previous studies have indicated that Bifidobacterium predominantly colonises the colon of infants 315 
and adults, as determined from faecal, mucosal scrapings or biopsy samples [38, 39], however, in 316 
this work (using a murine model), we have described SI-specific responses. From a translational 317 
perspective, in humans these protective cell shedding responses may result from bifidobacteria 318 
15 
 
cross-talk in the lower SI. Although difficult to measure in humans, previous studies have indicated 319 
Bifidobacterium colonisation in the lower SI (i.e. the ileum, as we observe in our model).  Notably, 320 
select studies using Ileostomy effluents and illeum biopsies have indicated Bifidobacteria (specifically 321 
B. animalis subsp. lactis and B. breve respectively) are present in this area of the infant and adult 322 
gastrointestinal (GI) tract [40, 41]. Therefore, in the human context, we may observe direct SI 323 
signalling via resident bifidobacteria and/or remote SI feedback signalling from colonic bifidobacteria 324 
epithelium cross-talk, which could be tested in future clinical intervention studies.   325 
As previously mentioned, studies have shown that this experimental model of LPS-induced cell 326 
shedding is driven by an induction in expression of TNF-α from the intestinal mucosa [22, 42]. One of 327 
the key functions of the gut microbiota is induction of tolerogenic or anti-inflammatory immune 328 
responses and thus we hypothesised that bifidobacteria may reduce cell shedding as a direct result 329 
of inhibiting TNF-α and macrophages – a potential source of TNF. However, we were unable to 330 
detect any changes in levels of TNF-α expression or macrophage infiltration from B. breve UCC2003-331 
treated or control (i.e. PBS) mice (Fig. 3C), suggesting that the protection conferred by 332 
Bifidobacterium strains is TNF-α independent. Previous studies have indicated that colonisation of B. 333 
breve UCC2003 during homeostatic conditions does not induce differences in splenic TNF-α-positive 334 
macrophage numbers when compared to non-colonised controls [7]. Coupled with the lack of 335 
change in expression in TNF-R1 following colonisation (Fig. 3H&I), it appears that macrophages, TNF-336 
α production and TNF-R1 signalling are not involved in modulating this protective response and 337 
suggests that B. breve UCC2003 acts preferentially from the luminal side through interactions with 338 
the intestinal epithelial cells. However, we cannot exclude the potential for EPS to block signalling 339 
via TNF-R1, however TNF-R1 expression appears to be restricted to the basolateral surface of 340 
epithelial cells and thus it would not be expected that B. breve (and thus the EPS) would have direct 341 
access to this cellular compartment for direct inhibition via binding [43]. Furthermore, quantification 342 
of downstream effectors (Fig. S3) including FADD, TRAF2 and caspase 2 and 8 does not significantly 343 
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differ between B. breve UCC2003 and B. breve UCC2003-del colonised mice, which suggests EPS does 344 
not play a key role via TNF-R1.   345 
To delineate these protective luminal bifidobacterial-epithelial interactions, we utilised epithelial-346 
specific MyD88 KO mice which is a key adaptor protein downstream of microbe-TLR signalling. 347 
Notably, mice carrying truncated epithelial MyD88 (i.e. C57BL/6 MyD88-/- villin-cre) showed no 348 
protection against cell shedding after colonisation of B. breve UCC2003 (Fig. 4B&D), which was in 349 
stark contrast to MyD88-positive control animals that again showed significant protection against 350 
LPS-induced cell shedding (Fig. 4A&C). Furthermore, we observed significant increases in IEC TLR2 351 
expression in B. breve UCC2003 colonised mice. Interestingly, previous work has indicated that TLR2 352 
may enhance ZO-1 associated intestinal epithelial barrier integrity [44], and other studies indicate 353 
that mice deficient in MyD88 signalling have increased susceptibility to intestinal inflammation [12]. 354 
In a UV model of apoptosis, MyD88 signalling appears to reduce caspase-3 and in turn increase cell 355 
survival and more recently B. bifidum has been shown to reduce apoptosis in vitro (necrotising 356 
enterocolitis IEC-6 cell model) also indicated by reduced CC3-positive cells [45]. Thus our data, in 357 
tandem with these studies, indicate that B. breve UCC2003 may regulate epithelial integrity in 358 
response to LPS-induced cell shedding (as marked by caspase-3) via these central MyD88 signalling 359 
mechanisms, potentially downstream of TLR2. 360 
 361 
Having determined the importance of host molecule MyD88, we next sought to determine if there 362 
was a specific bifidobacterial molecule central to the observed protective response. Since we have 363 
previously shown that the surface EPS of B. breve UCC2003 can regulate the host response [7], we 364 
investigated the ability of an EPS mutant, B. breve UCC2003-EPSdel (complete deletion of eps 365 
biosynthetic cluster) to modulate LPS-induced cell shedding. Notably, mice receiving B. breve 366 
UCC2003-EPSdel showed no significant protection against cell shedding when compared to EPS-367 
positive (i.e. B. breve UCC2003) colonised mice (Fig. 5A&C), suggesting an important role for this EPS 368 
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in microbe-host crosstalk. Importantly, EPS structures can be recognised via TLR2 (and signal via 369 
MyD88) and previous work with the Polysaccharide A (PSA) capsule of Bacteroides fragilis highlights 370 
that PSA can modulate dendritic cell and T regulatory cell function via TLR2 signalling [46, 47]. 371 
Additionally, previous work has highlighted that a strain of B. breve (Yakult strain) can also induce IL-372 
10 producing T regulatory cells via TLR2, however they did not determine if this was via an EPS-373 
specific mechanisms [48]. Furthermore, recent studies using Bacillus subtilis have demonstrated that 374 
the EPS capsule of this bacterium is able to protect against intestinal inflammation in a murine 375 
model of colitis (in this instance via TLR4), providing further support for the likely role of 376 
bifidobacterial EPS in the effects observed in these studies [49]. Notably, the probiotic genus 377 
Lactobacillus also produces distinct EPSs, which are structurally similar to those observed in 378 
bifidobacteria [50]. Recently, within an in vitro system (HT29-19A epithelial cell line), the EPS from 379 
Lactobacillus acidophilus 5e2 was shown to increase IL-8 expression and also TLR2 expression (we 380 
also observe that B. breve UCC2003 induces IEC TLR2 expression), and additionally up-regulation of 381 
TLR2 was found to potentially ‘sensitise’ epithelial cells to subsequent stimulation with 382 
peptidoglycan (a TLR2 agonist) [51]. Furthermore, the authors also observed a modest increase in 383 
TLR4 expression after addition of EPS, but did not detect any significant modulation of IL-8 responses 384 
after priming with EPS and subsequent addition of LPS, which may indicate less of a role for EPS-385 
TLR4 interactions [51]. From a more systemic perspective, in the instance that Lactobacillus or 386 
indeed B. breve UCC2003 potentially translocate across the epithelial barrier, it maybe be expected 387 
they could directly influence macrophage function and previous studies have shown that L. casei 388 
Shirota can dampen down inflammatory macrophages responses and L. rhamnosus EPS has also 389 
been shown to modulate macrophage function in vitro, but on this occasion induce pro-390 
inflammatory responses [52, 53]. Ideally we would test our B. breve strains in TLR2 and/or TLR4 KO 391 
animals; unfortunately, previous work has shown that these mice do not respond to LPS and thus 392 
would not have a cell shedding response making these further studies not possible. However, in 393 
studies using RNAscope, we found significant numbers of B. breve UCC2003 associated with the villi 394 
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in colonised mice (Fig. S2), suggesting that direct signalling interactions between the bacteria 395 
(possibly via EPS and TLRs, and B. breve UCC2003 colonisation increases TLR2 expression) and IECs 396 
may play an important role in modulating this response. These data alongside our findings suggest 397 
that B. breve EPS may regulate cell shedding by acting as TLR ligands via MyD88, leading to 398 
protective epithelial responses.  399 
 400 
To probe these EPS-epithelial interactions further we took advantage of the bi-directional eps gene 401 
cluster in B. breve UCC2003 which can express two genetically and importantly chemically distinct 402 
surfaces EPSs [7]. All previous studies utilised EPS1 (i.e. with B. breve UCC2003), but we also 403 
determined responses following EPS2 (i.e. B. breve UCC2003-EPSInv) colonisation. Strikingly and 404 
contrary to our expectations we found that this isogenic strain was unable to confer protection 405 
against LPS-induced cell shedding (Fig. 5B&D). Importantly, EPSs are comprised of repeating mono- 406 
or oligosaccharides linked by various glycosidic linkages, and the three dimensional structures and 407 
other physiochemical features of EPSs can vary widely [54]. The variability in chemical composition 408 
of these two B. breve EPSs (previous work suggests the EPSs may include glucose, galactose and/or 409 
the N-acetylated versions of these two sugars in different ratios or composition [7]) could in part 410 
explain the different modulatory properties of this beneficial microbe in relation to receptor-ligand 411 
binding and further highlights the issues with significant strain (or in this case isogenic), variation in 412 
effects on host responses. Importantly, these different EPS-epithelium protective responses do not 413 
appear to be linked to colonisation ability as all strains colonised mice at similar levels (Fig. S1). 414 
Previous limited studies have indicated that specific chemical structures of EPSs such as PSA of B. 415 
fragilis (comprised of an unusual repeating tetrasaccharide moiety, free carboxyl, phosphate, and 416 
amino groups, that contribute to its zwitterionic nature) is important for function [46]. Additionally, 417 
in vitro studies on L. reuteri  strains (DSM 17938  and L26 Biocenol™) indicates both EPSs are high 418 
molecular weight d-glucan polysaccharides with differing spatial conformations, which may relate to 419 
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induction of different cytokine responses, however the direct chemical structures involves in this 420 
modulation have yet to be defined [55]. Future challenges will include studies to fully chemically 421 
characterise the different strains of ‘probiotic’ bacteria, as evidently, significant differences in 422 
response to small strain variations (including variations in EPS expression and structure and also 423 
other MAMPS) may impact beneficial host responses [56, 57]. 424 
 425 
We have previously shown that EPS-positive B. breve UCC2003 does not induce inflammatory host 426 
responses after colonisation, which we hypothesise is to the advantage of the bacterium and host 427 
for maintaining efficient symbiosis and homeostasis [7]. Interestingly, when we probed the 428 
downstream signalling transcriptional events after colonisation and LPS challenge we determined 429 
that presence of EPS1 (i.e. B. breve UCC2003) appeared to attenuate apoptosis-induced signalling 430 
activation, which was in stark contrast to mice colonised with the B. breve UCC2003-EPSdel strain 431 
which had significantly elevated apoptotic gene expression (Fig. 6). Importantly, previous work has 432 
demonstrated that activation of MyD88 can downregulate several of these genes including Fas 433 
(CD95) [58]. Fas is a cell surface receptor and member of the TNF superfamily and when bound by its 434 
ligand it induces apoptosis through the assembly of a multiprotein complex called the DISC which in 435 
turn activates caspase 8 (i.e. extrinsic apoptosis pathway) [59]. Further evidence of an EPS-specific 436 
mechanism attenuating epithelial apoptosis comes from observation that Bad, Cycs, casp4, Traf5 437 
and Tnfr9 are upregulated in the intestinal mucosa of mice colonised by B. breve UCC2003-del 438 
compared to B. breve UCC2003 colonised mice. Bad is a pro-apoptotic (BH3-only) member of the bcl-439 
2 family that antagonises the anti-apoptosis proteins bcl-2, bcl-xl and bcl-2 allowing the activation of 440 
bax/bak oligomers and the release of cytochrome c from the mitochondria. Within the same 441 
pathway, Cycs encodes the heme protein cytochrome c, which forms a multiprotein complex called 442 
the apoptosome which activates a cascade of proteases called caspases which cause apoptotic cell 443 
death [60]. Traf5 is a scaffold protein that forms a multiprotein complex with TRAF2, RIP1 and the 444 
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TNF receptor and potentially can mediate the activation of apoptosis and NF-B [61]. We have 445 
previously shown that NF-B1 inhibits LPS-induced apoptotic cell shedding whereas NF-B2 446 
stimulates apoptotic cell shedding [22]. TNFRF9 (CD137) is expressed on T cells and has been 447 
reported to enhance their cytolytic activity [62]. These data strongly suggest that mechanistically B. 448 
breve UCC2003, via EPS, may block intrinsic and extrinsic apoptosis signalling (via activation of 449 
MyD88) during inflammation to protect epithelial cells under highly apoptotic conditions.  450 
 451 
In summary, we have demonstrated that certain bifidobacteria, i.e. B. breve UCC2003 are able to 452 
protect against pathologic cell shedding induced by IP injection of LPS and that this protection 453 
appears to be independent of TNF-α production by resident tissue macrophages. Using wild type and 454 
mutant B. breve, we have demonstrated that a specific EPS is able to confer this protection, and 455 
using knockout mice, have shown that this protection appears contingent on functional signalling 456 
downstream of the epithelial TLR family members and modulation of pro-apoptotic gene pathways. 457 
Understanding how health promoting species of bacteria such as the Bifidobacterium genus interact 458 
with the intestinal epithelium and how these species confer their protective effects may drive 459 
progress toward understanding how pathologic cell shedding in IBD patients is linked to changes in 460 
the intestinal microbiota. Future human studies could be considered to address issues of microbial 461 
dysbiosis and relation to the cell shedding response and to what extent microbial dysbiosis is linked 462 
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Figures and Figure legends 681 
 682 
Figure 1: LPS challenge induces cell shedding from the small intestinal villi 683 
C57BL/6 mice were administered either (A) PBS (control) or (B) LPS by IP injection and proximal 684 
small intestines removed after 1.5 h for immunohistochemistry and stained with anti-CC3 (i.e. brown 685 
cells indicate shedding event), also highlighted by arrows. A representative picture for each group is 686 









Figure 2: B. breve UCC2003 protect against LPS-induced cell shedding 694 
C57 BL/6 mice received three daily oral gavage doses of (A) PBS or (B) ~1 x 109 B. breve UCC2003 695 
followed by IP challenge with LPS 24 h later, representative picture shown. Formalin fixed, paraffin-696 
embedded intestinal sections were stained with anti-CC3 and (C) quantified using the WinCrypts and 697 
Score programs, 20 well orientated hemi-villi were counted/mouse. Data are mean ± SD, n = 12 (2 698 




Figure 3: The cytoprotective effect of B. breve is not mediated by the TNF-α signalling pathway 701 
C57BL/6 mice were gavaged with PBS or B. breve and challenged with PBS or LPS for 1.5 h. Columns 702 
show TNF-α levels (via ELISA) in (A) whole small intestine intestinal homogenates or (B) plasma ± SD. 703 
(C) Representative immuno-histochemical staining for F4/80+ macrophages (brown cells) in control 704 
34 
 
or B. breve colonised mice. (D) Western blot analysis (F4/80 or house-keeping β-actin) of whole 705 
small intestinal homogenates, with (E) columns showing relative density of F4/80 from (from D) 706 
whole intestinal homogenates. (F) Columns show F4/80 expression via RT-PCR  ± SD. (G) 707 
Representative histology image of epithelial cell stripping protocol (modified Weiser method) leaving 708 
LP intact (as indicated by arrows) and (H) FACS analysis for purity (anti-CD45). (I) Columns shown 709 
TNF-R1 expression via RT-PCR ± SD and (J) Western blotting for protein expression in isolated 710 
intestinal epithelial cells, with (K) columns showing relative density of TNF-R1 (from J). . n = 9 mice 711 
per group are representative of three experiments analysed with ANOVA Kruskal–Wallis test with 712 








Figure 4: The cytoprotective effect of B. breve is MyD88 dependent 719 
(A, B) IEC MyD88+/+ mice and (C, D), IEC MYD88-/- mice were gavaged with PBS (control) or B. breve 720 
and challenged with LPS. Paraffin-embedded intestinal sections were stained with anti-CC3 and 721 
quantified using the WinCrypts and Score programs. (E) Columns shown TLR2 expression via RT-PCR. 722 




Figure 5: B. breve EPS plays a role in modulating the cytoprotective effect 725 
C57BL/6 mice were gavaged with either B. breve UCC2003 or (A, B) B. breve UCC2003del (i.e. EPS-726 
negative) or (C, D) B. breve UCC2003inv (i.e. EPS2). Formalin fixed, paraffin-embedded intestinal 727 
sections were stained with anti-CC3 and quantified using the WinCrypts and Score programs. Data 728 




Figure 6: B. breve EPS attenuates inflammatory and apoptosis signalling  731 
Whole small intestinal homogenates from LPS challenged (A) B. breve UCC2003-EPSdel and (B) B. 732 
breve colonised mice compared to control (i.e. PBS) were analysed using a custom RT-PCR array. 733 
Data are mean ± SD, n = 6 (two independent experiments), *P < 0.05 and **P < 0.01 and analysed 734 




Supplementary Information 737 
 738 
Supplementary Figure 1: B. breve strains stably colonise murine GI tract. 739 
Faecal samples were collected from control (i.e. PBS), B. breve UCC2003, B. breve UCC2003-del and 740 
B. breve UCC2003-inv colonised mice on day 4 (after 3 x 24 h doses at ~1 x 109) and plated on RCA (+ 741 




Supplementary Figure 2: B. breve UCC2003 does not notably impact faecal microbiota profiles. 744 
Faecal samples from control (i.e. PBS) and B. breve UCC203 (after 3 x 24 h doses at  ~1 x 109) were 745 
collected and processed for 16s Illumina sequencing. (A) Pie chart depicting comparison of average 746 
taxonomic content for two groups at class level taxonomic profile. (B) Individual boxplot of each taxa 747 
40 
 
at class level taxonomic profile for two groups (i.e. control and B. breve UCC2003), where read 748 


















Supplementary Figure 3: B. breve UCC2003 resides in close contact with the small intestinal 765 
epithelium. Representative RNAscope staining for B. breve (B. breve specific probe) brown cells and 766 







Supplementary Figure 4:  Bifidobacterial EPS modulates cell shedding. 772 
Combination of counts from Figures 2, 4 and 5 to provide representative overview of LPS-induced 773 
cell shedding responses between B. breve strains.  C57BL/6 mice were gavaged (3 x 24 h doses at ~1 774 
x 109) with either B. breve UCC2003 or B. breve UCC2003del (i.e. EPS-negative) or B. breve 775 
UCC2003inv (i.e. EPS2) and challenged with LPS. (A) Formalin fixed, paraffin-embedded intestinal 776 
sections were stained with anti-CC3 and quantified using the WinCrypts and Score programs along 777 
villus length, (B) average percentage of total caspase-3 positive events. Data are mean ± SD, n = 778 





Supplementary Figure 5: Whole small intestinal homogenates from LPS challenged (A, B) B. breve 782 
UCC2003-EPSdel and (C, D) B. breve colonised mice compared to control (i.e. PBS) were subjected to 783 
44 
 
custom array RT-PCR. Data are mean ± SD, n = 6 (two independent experiments), *P < 0.05 and **P < 784 




RNAscope was performed using a commercial kit from Advanced Cell Diagnostics (California, USA) as 787 
per the manufacturer’s instructions. Briefly, 5 μm formalin fixed paraffin embedded small intestinal 788 
tissue was mounted on Superfrost plus slides (ThermoFisher) before baking in a dry oven at 60oC for 789 
1 h. Slides were then deparaffinised with Xylene and 100% ethanol before applying Pre-treat 790 
solution 1 for 10 minutes at room temperature. Slides were then washed in distilled water before 791 
incubating in boiling Pre-treat 2 solution for 15 minutes. Following further washes, Pre-treat solution 792 
3 was applied in a humidified chamber at 40oC for 30 minutes. After further washes, B. breve 793 
UCC2003 specific probe or Cyclophylin B control probe was hybridised to the slides for 2 h at 40oC. 794 
Following washing in wash buffer, a series of amplification probes (AMP1 to AMP6) were 795 
sequentially bound and washed to/from the slides before signal detection using DAB substrate as 796 
per the manufacturer’s recommendations. Slides were then counterstained with haematoxylin, 797 
dehydrated and mounted for visualisation. 798 
Faecal DNA extractions, quantification and sequencing 799 
DNA was extracted from murine faecal samples using the FastDNATM SPIN Kit for Soil (MP 800 
Biomedicals) following the manufacturer’s instructions but incorporating an extension of the initial 801 
bead-beading time to three minutes. 802 
The concentration of bacterial DNA was quantified using Qubit and normalised to 5 ng ml-1 for all 803 
samples. Extracted DNA was used as a template for PCR amplification of the V4 region of the 16S 804 
rRNA gene, 5’ AAT GAT ACG GCG ACC ACC GAG ATC TAC A and, 5’ CAA GCA GAA GAC GGC ATA CGA 805 
GAT AAC T. Amplification conditions of the PCR were: 1 cycle of 94°C 3 min and 25 cycles of 94°C for 806 
45 s, 55°C for 15 s and 72°C for 30 s using a 96 well Thermal Cycler PCR machine. 16S RNA gene 807 




Sequence processing 810 
All raw sequence reads were processed through quality control using FASTX-Toolkit [63] keeping a 811 
minimum quality threshold of 33 for at least 50% of the bases. Reads that passed the threshold were 812 
aligned against SILVA database (version: SILVA_119_SSURef_tax_silva) [64] using BLASTN (ncbi-blast-813 
2.2.25+; Max e-value 10e-3) [65] separately for both pairs. After performing the BLASTN alignment, 814 
all output files were imported and annotated using the paired-end protocol of MEGAN [66]. 815 
Taxonomic annotation 816 
For processing the BLAST files by MEGAN6, we used parameter settings of “Min Score = 50”, “Top 817 
Percent = 10”. Some reads which did not have any match to the respective database were placed 818 
under a “No hit” node, and some reads that were originally assigned to a taxon that did not meet 819 
our selected threshold criterion were pushed back using the lowest common ancestor (LCA) 820 
algorithm to higher nodes where the threshold was met. After importing datasets in MEGAN, we 821 
obtained MEGAN-own “rma files” for each data mapped onto NCBI taxonomy based on our selected 822 
threshold. Further, all the files were compared and analysed within MEGAN. 823 
 824 
Statistical analysis  825 
For microbiota analysis R software was used [67].  Average community profile comparison of two 826 
groups are displayed using pie charts in MEGAN. Abundance matrices were depicted using boxplots 827 
in R for each taxa showing comparison of two groups.  828 
 829 
